119271-78-2|Sezolamide hydrochloride|(+)-(S)-5,6-Dihydro-4-(isobutylamino)-4H-thieno(2,3-b)thiopyran-2-sulfonamide, 7,7-dioxide, monohydrochloride|-范德生物科技公司

Sezolamide hydrochloride

NMR下载 COA and HPLC MSDS下载
names：
(+)-(S)-5,6-Dihydro-4-(isobutylamino)-4H-thieno(2,3-b)thiopyran-2-sulfonamide, 7,7-dioxide, monohydrochloride
CAS号：
119271-78-2
MDL Number：
MF(分子式)： C11H19ClN2O4S3 MW(分子量)： 374.91
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	(+)-(S)-5,6-Dihydro-4-(isobutylamino)-4H-thieno(2,3-b)thiopyran-2-sulfonamide, 7,7-dioxide, monohydrochloride
英文别名	Sezolamide hydrochloride; Sezolamide HCl; Sezolamide; MK 417; MK-417.
CAS号	119271-78-2
Inchi	InChI=1S/C11H18N2O4S3.ClH/c1-7(2)6-13-9-3-4-19(14,15)11-8(9)5-10(18-11)20(12,16)17;/h5,7,9,13H,3-4,6H2,1-2H3,(H2,12,16,17);1H/t9-;/m0./s1
InchiKey	VYZDSLFBCSLIEA-FVGYRXGTSA-N
分子式 Formula	C11H19ClN2O4S3
分子量 Molecular Weight	374.91
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Sezolamide hydrochloride(CAS:119271-78-2):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Sezolamide hydrochloride is a potent topical carbonic anhydrase inhibitor for the study of its ocular hypotensive activity in patients with elevated intraocular pressure.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Gunning FP, Greve EL, Bron AM, Bosc JM, Royer JG, George JL, Lesure P, Sirbat D. Two topical carbonic anhydrase inhibitors sezolamide and dorzolamide in Gelrite vehicle: a multiple-dose efficacy study. Graefes Arch Clin Exp Ophthalmol. 1993 Jul;231(7):384-8. PubMed PMID: 8406063.

[2]Gunning F, Béchetoille A, Lippa EA, Pfeiffer N, Gerling J, Holder D, Clineschmidt C, Buntinx A, Brunner-Ferber FL, Grehn F, et al. Sezolamide: additivity to timolol twice daily. Eye (Lond). 1992;6 ( Pt 5):525-9. PubMed PMID: 1286720.

[3] Buclin T, Biollaz J, Lippa EA, Brunner-Ferber F, van Melle G, Munafo A, Clineschmidt C, Schelling JL. Absence of metabolic effects of the topical carbonic anhydrase inhibitors MK-927 and sezolamide during two-week ocular administration to normal subjects. Clin Pharmacol Ther. 1991 Jun;49(6):665-73. PubMed PMID: 2060255.

[4] Lippa EA, Schuman JS, Higginbotham EJ, Kass MA, Weinreb RN, Skuta GL, Epstein DL, Shaw B, Holder DJ, Deasy DA, et al. MK-507 versus sezolamide. Comparative efficacy of two topically active carbonic anhydrase inhibitors. Ophthalmology. 1991 Mar;98(3):308-12; discussion 312-3. PubMed PMID: 2023750.

[5] Bron A, Lippa EA, Gunning F, Bénichou C, Lesure P, Sirbat D, Royer J, Flament J, Clineschmidt C, Panebianco D, et al. Multiple-dose efficacy comparison of the two topical carbonic anhydrase inhibitors sezolamide and MK-927. Arch Ophthalmol. 1991 Jan;109(1):50-3. PubMed PMID: 1987948.

6: Pfeiffer N, Greve E, Béchetoille A, Lippa EA, Jaquet-Müller F, Gunning F, Gerling J, Grehn F. [Additive effect of timolol and the local carbonic anhydrase inhibitor MK-417 (sezolamide)]. Fortschr Ophthalmol. 1991;88(6):846-7. German. PubMed PMID: 1794818.

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开